Cargando…

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study

OBJECTIVE: To estimate the rate of lower limb amputation among adults newly prescribed canagliflozin according to age and cardiovascular disease. DESIGN: Population based, new user, cohort study. DATA SOURCES: Two commercial and Medicare claims databases, 2013-17. PARTICIPANTS: Patients newly prescr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fralick, Michael, Kim, Seoyoung C, Schneeweiss, Sebastian, Everett, Brendan M, Glynn, Robert J, Patorno, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445737/ https://www.ncbi.nlm.nih.gov/pubmed/32843476 http://dx.doi.org/10.1136/bmj.m2812

Ejemplares similares

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
por: Patorno, Elisabetta, et al.
Publicado: (2018)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2019)

Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
por: Zhuo, Min, et al.
Publicado: (2022)

A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes
por: Fralick, Michael, et al.
Publicado: (2021)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments
por: Schneeweiss, Sebastian, et al.
Publicado: (2021)

Risk of Ischemic Cerebrovascular and Coronary Events in Adult Users of Anticonvulsant Medications in Routine Care Settings
por: Patorno, Elisabetta, et al.
Publicado: (2013)

COMPARATIVE PERFORMANCE OF FOUR CLAIMS-BASED FRAILTY MEASURES IN THE UNITED STATES MEDICARE DATA
por: Kim, Dae H, et al.
Publicado: (2019)

Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model
por: Lee, Moa P, et al.
Publicado: (2020)

Benzodiazepines and risk of all cause mortality in adults: cohort study
por: Patorno, Elisabetta, et al.
Publicado: (2017)

Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study
por: Kang, Eun Ha, et al.
Publicado: (2018)

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
por: Budoff, Matthew J., et al.
Publicado: (2017)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
por: Skelley, Jessica W, et al.
Publicado: (2018)

Misclassification of Obesity in Claims Data
por: Suissa, Karine, et al.
Publicado: (2021)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Rates and risk factors for amputation in people with diabetes in Japan: a historical cohort study using a nationwide claims database
por: Kaneko, Masanori, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Prospective Monitoring of Newly Marketed Drugs in Frail Older Adults Using Real-World Databases
por: Kim, Dae, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
por: Kaze, Arnaud D., et al.
Publicado: (2022)

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
por: Carbone, Salvatore, et al.
Publicado: (2019)

Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study
por: Kim, Kyung-Soo, et al.
Publicado: (2022)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Desmopressin and the risk of hyponatremia: A population-based cohort study
por: Fralick, Michael, et al.
Publicado: (2019)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

The risk of major cardiovascular events for adults with transfemoral amputation
por: Mundell, Benjamin F., et al.
Publicado: (2018)

Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores
por: Peters, Kirsten E., et al.
Publicado: (2023)

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
por: Ryan, Patrick B., et al.
Publicado: (2018)

Comparative safety of anesthetic type for hip fracture surgery in adults: retrospective cohort study
por: Patorno, Elisabetta, et al.
Publicado: (2014)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study
por: Park, Yoonyoung, et al.
Publicado: (2018)

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
por: Zhou, Zien, et al.
Publicado: (2019)

Assessment of Hospital Readmission Rates, Risk Factors, and Causes After Cardiac Arrest: Analysis of the US Nationwide Readmissions Database
por: Yeo, Ilhwan, et al.
Publicado: (2019)

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial
por: Rasmussen, Daniel Guldager Kring, et al.
Publicado: (2022)

Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
por: Zhuo, Min, et al.
Publicado: (2021)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)

Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset
por: Patorno, Elisabetta, et al.
Publicado: (2020)

Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study
por: Desai, Rishi J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u27ncgv1oecj7i4ce96j6itg6v